PT-141 (bremelanotide): the science of a melanocortin peptide
PT-141, known generically as bremelanotide, takes a different approach to sexual health than the well-known pills. Instead of acting on blood flow, it acts on pathways in the brain. This guide explains what PT-141 is, its specific FDA-approved use, how it works, what the evidence shows, and how a provider prescribes it.
What is PT-141?
PT-141 (bremelanotide) is a melanocortin receptor agonist. It is FDA approved under the brand Vyleesi for one specific use: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It was approved in 2019 and is taken as needed before activity.
Being precise about the approval matters. Use in men or in postmenopausal women is off-label, meaning it is not an FDA-approved or established use, and the evidence in those groups is more limited. A provider decides whether it is appropriate for you.
At Expert Health, PT-141 is prescribed by a US-licensed provider. Its only FDA-approved use is HSDD in premenopausal women; other uses are off-label. Content here is educational, not medical advice. See the disclaimer below.
How PT-141 works
Unlike the common erectile dysfunction pills, which work on blood flow (the PDE5 pathway), PT-141 works in the central nervous system. It activates melanocortin receptors in the brain that are involved in sexual desire and arousal, which is why it is described as acting on desire rather than purely on the mechanics of blood flow.
- Acts in the brain, on melanocortin pathways tied to desire and arousal.
- Different from PDE5 pills, which act on blood flow rather than desire.
- Taken as needed, ahead of anticipated activity, not daily.
What the research shows
PT-141's approval rests on two large phase 3 trials (the RECONNECT program, around 1,250 premenopausal women with HSDD). Compared with placebo, bremelanotide significantly improved scores for sexual desire and reduced the distress associated with low desire.
That evidence is specific to premenopausal women with HSDD. For other populations, including men, the controlled evidence is more limited, which is why honest framing and a provider's judgment matter. Trial results are averages, and individual responses vary.
Who it's for
PT-141's clearest, evidence-backed use is for premenopausal women with acquired, generalized HSDD. Other uses are off-label and call for a careful conversation with a provider about what is and isn't established. A provider reviews your history and confirms whether it is appropriate.
Safety and side effects
The most common side effects are nausea, flushing, headache, and reactions at the injection site. PT-141 can cause a temporary increase in blood pressure and a decrease in heart rate after each dose, usually resolving within hours, so it is not appropriate for people with uncontrolled high blood pressure or certain heart conditions. This is exactly why provider screening matters and it should never be a gray-market purchase.
Frequently asked questions
What is PT-141 approved for?
How is PT-141 different from ED pills?
How is PT-141 taken?
Sources
- Vyleesi (bremelanotide injection) Prescribing Information · U.S. FDA Label
- Vyleesi (bremelanotide) label and indication · DailyMed / National Library of Medicine
This article is for educational purposes and is not medical advice. Statements have not been evaluated by the FDA, and this treatment is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Individual results vary. Always consult a licensed provider before starting any treatment.
Explore other libido options.
Ready to see if PT-141 is right for you?
Book a free, no-obligation consult. A US-licensed provider reviews your goals and history and tells you straight, no pressure either way.
See if I qualify